Application of sample size re-estimation in clinical trials: A systematic review

• Published in: Contemporary clinical trials communications 2023-12, Vol.36, p.101210-101210, Article 101210
• Main Authors: Mano, Hirotaka, Tanaka, Yuji, Orihara, Shunichiro, Moriya, Junji
• Format: Article
• Language: English
• Subjects: Adaptive design; Clinical trial; Sample size re-estimation; Systematic review
• ISSN: 2451-8654; 2451-8654
• DOI: 10.1016/j.conctc.2023.101210

Sample size re-estimation (SSR) is a method used to recalculate sample size during clinical trial conduct to address a lack of adequate information and can have a significant impact on study size, duration, resources, and cost. Few studies to date have summarized the conditions and circumstances under which SSR is applied. We therefore performed a systematic review of the literature related to SSR to better understand its application in clinical trial settings. PubMed was used as the primary search source, supplemented with information from ClinicalTrials.gov where necessary details were lacking from PubMed. A systematic review was performed according to a pre-specified search strategy to identify clinical trials using SSR. Features of SSR, such as study phase and study start year, were summarized. In total, 253 publications met the pre-specified search criteria and 27 clinical trials were subsequently determined as relevant in SSR usage. Among trials where the study phase was provided, 2 (7.4%) trials were Phase I, 5 (18.5%) trials were Phase II, 11 (40.7%) trials were Phase III, and 2 (7.4%) trials were Phase IV. Our results showed that SSR is also used in Phase I and II, which involve earlier decision making. We expect that SSR will continue to be used in early-phase trials where sufficient prior information may not be available. Furthermore, no major trends were observed in relation to therapy area or type of SSR, meaning that SSR may become a feasible and widely applied method in the future.